中药药理与临床2025，Vol.41Issue(2)：60-64,5.
凉血和营方治疗血栓闭塞性脉管炎临床疗效及对内皮细胞活化的影响
Clinical Efficacy of Liangxue Heying(凉血和营)Formula in the Treatment of Thromboangiitis Obliterans and Its Effect on Endothelial Cells
摘要
Abstract
Objective:To observe the clinical efficacy of Liangxue Heying(凉血和营)Formula in treating thromboangiitis obliterans(TAO)and its impact on the activation of endothelial cells.Methods:Seventy TAO patients(stage II or higher)with the syndrome of Shire Dusheng(湿热毒盛),treated between December 2020 and January 2023 at the Department of Vascular Medicine,Shanghai TCM-Integrated Hospital,Shanghai University of TCM,were selected.They were randomly divided into a control group and a treatment group,with 35 in each group.Both groups received conventional primary treatment,and the treatment group was additionally given Liangxue Heying Formula over a 28-day period.The clinical efficacy,symptom and sign scores,laboratory tests(inflammatory markers,vascular endothelial cell function,coagulation function),safety indices,and adverse effects were analyzed to evaluate the effect of Liangxue Heying Formula in the treatment of TAO.Results:Five patients dropped out during the study,and 33 in the control group and 32 in the treatment group were finally included.Both groups showed therapeutic effects after treatment,with improved symptom scores(P<0.01),and the treatment group outperformed the control group in clinical efficacy(P<0.01).Liangxue Heying Formula significantly enhanced the effective treatment rate for TAO(P<0.05),and improved the clinical symptoms,especially limb coldness,numbness,and resting pain(P<0.05,P<0.01).Inflammatory indices such as WBC,NEUT,ESR,hs-CRP,FIB,IL-6,and VCAM-1 in peripheral blood were all reduced after treatment in both groups(P<0.01).The ICAM-1 level was unchanged in the control group but significantly decreased in the treatment group(P<0.01).Compared with the control group,the treatment group manifested marked reductions in WBC,NEUT,ESR,hs-CRP,FIB,IL-6,and adhesion molecules ICAM-1 and VCAM-1(P<0.01).Conclusion:Liangxue Heying Formula could attenuate endothelial cell activation in TAO patients and ameliorate the clinical symptoms in individuals with the syndrome of Shire Dusheng.关键词
血栓闭塞性脉管炎/凉血和营方/湿热毒盛/内皮细胞活化Key words
Thromboangiitis obliterans/Liangxue Heying(凉血和营)Formula/Syndrome of Shire Dusheng(湿热毒盛)/Endothelial cell activation引用本文复制引用
冯夏,梁新雨,祝艳丹,王御震,杨建飞,曹烨民..凉血和营方治疗血栓闭塞性脉管炎临床疗效及对内皮细胞活化的影响[J].中药药理与临床,2025,41(2):60-64,5.基金项目
国家自然科学基金(编号:82174382、82104486) （编号:82174382、82104486）
国家科技重大专项(编号:2019ZX09201004-002-091) （编号:2019ZX09201004-002-091）
上海市2020年度科技创新行动计划项目(编号:20Z21900200) （编号:20Z21900200）
上海市十三五临床重点专科(中医外科) （中医外科）
上海市卫生健康委员会中医药科研项目(编号:2024QN010). （编号:2024QN010）
